Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Diphenhydramine; Methylprednisolone; Mycophenolate mofetil; Mycophenolate mofetil; Paracetamol; Prednisone
- Indications Lupus nephritis
- Focus Registrational; Therapeutic Use
- Acronyms LUNAR
- Sponsors Genentech; Roche
- 15 Nov 2023 Initial post hoc analysis of patients in the control arms of the LUNAR and BELONG trial presented at the ACR Convergence 2023
- 01 Mar 2023 Results comparing differences between B-cell depletion in lupus nephritis patient populations who received rituximab (LUNAR), ocrelizumab (BELONG), or obinutuzumab (NOBILITY), published in the Clinical Immunology
- 24 Oct 2018 Results assessing changes in blood pressure and proteinuria of this and LUNAR trial from baseline to 1-year in patients with lupus nephritis, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.